Cedars-Sinai Biomanufacturing
Los Angeles, CA
National Center
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
79.8
Signal Score
✓ FDA Inspections (1)
✓ Clinical Trials (34)
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Cedars-Sinai Biomanufacturing
- Signal Score
- 79.8/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Los Angeles, CA
- Modalities
- Cell Therapy, Gene Editing
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Cedars-Sinai Biomanufacturing
CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-03-14)
Operations
78.4
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, Gene Editing
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT06208878
A Long-term Follow-up Study of Subjects Who Received CRISPR...
NA
Enrolling By Invitation
NCT05487599
A Clinical Trial of PR001 (LY3884961) in Patients With...
PHASE1/PHASE2
Active Not Recruiting
NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients...
PHASE1/PHASE2
Recruiting
View all 34 programs →
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Stability
68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Cedars-Sinai Biomanufacturing FDA Inspection History
2025-03
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-03-14 |
Cedars-Sinai Medical Center
West Hollywood, California
Facility-linked
|
Blood and Blood Products | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Oct 07, 2026
Clinical Activity 34 studies
NCT07676435
Ongoing Lung Decline With Age Intensified Response
PHASE2
Recruiting
NCT07676643
ELIXIR MDTM Satisfaction Clinical Trial
NA
Active Not Recruiting
NCT06208878
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
NA
Enrolling By Invitation
NCT05781152
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With...
PHASE4
Recruiting
NCT05819359
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of...
PHASE2
Active Not Recruiting
NCT05487599
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral...
PHASE1/PHASE2
Active Not Recruiting
NCT05306457
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
PHASE1
Active Not Recruiting
NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced...
PHASE1/PHASE2
Recruiting
NCT04284293
CNS10-NPC for the Treatment of RP
PHASE1
Active Not Recruiting
NCT04681131
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
PHASE2
Completed
NCT04669899
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor,...
PHASE1/PHASE2
Completed
NCT03751709
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
PHASE1
Completed
NCT04224558
Stem Cell Transplantation in Crohn's Disease
PHASE1/PHASE2
Recruiting
NCT04035434
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or...
PHASE1/PHASE2
Terminated
NCT04048577
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week...
PHASE4
Unknown
NCT03859388
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab...
NA
Active Not Recruiting
NCT03508609
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary...
PHASE2
Completed
NCT03145298
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
PHASE1
Completed
NCT02943850
CNS10-NPC-GDNF for the Treatment of ALS
PHASE1
Completed
NCT02684006
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell...
PHASE3
Completed
+ 14 more studies
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Frequently Asked Questions About Cedars-Sinai Biomanufacturing
How many FDA inspections does Cedars-Sinai Biomanufacturing have on record?
CDMO Signal tracks 1 FDA inspection for Cedars-Sinai Biomanufacturing, sourced from the FDA inspection database. See the full inspection history above.
Has Cedars-Sinai Biomanufacturing received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Cedars-Sinai Biomanufacturing.
How many clinical programs is Cedars-Sinai Biomanufacturing linked to?
Cedars-Sinai Biomanufacturing is associated with 34 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Cedars-Sinai Biomanufacturing's CDMO Signal Score?
Cedars-Sinai Biomanufacturing has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cedars-Sinai Biomanufacturing for a manufacturing program?
Use the free AI matchmaker to compare Cedars-Sinai Biomanufacturing against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Bayer (Cell Therapy Mfg)
Berkeley, CA
Signal Score: 80.4
Cell Therapy, Gene Editing
Green Phoenix Labs
San Diego, CA
Signal Score: 78.1
Cell Therapy, Gene Editing
Applied StemCell
Milpitas, CA
Signal Score: 59.0
Cell Therapy, Gene Editing
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing